+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID06365788

Phase II Study of Bicalutamide and Abemaciclib for Women With Advanced Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2026-04-01

53

Participants Needed

6

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of abemaciclib and bicalutamide in women with androgen receptor positive metastatic triple negative breast cancer. This phase II clinical trial focuses on patients who have advanced, unresectable, or metastatic disease that has progressed after at least one prior cytostatic treatment. The study aims to assess whether this drug combination can help control the disease and to evaluate its safety. Participants will receive abemaciclib tablets orally twice daily at a dose of 150 mg, along with bicalutamide tablets orally once daily at 150 mg. Treatment will continue until the disease progresses or unacceptable side effects occur. This single-arm study does not include a comparison group and monitors disease control and adverse events over time. During the study, participants will undergo regular assessments including imaging to measure disease control at specific time points such as 16 and 24 weeks. Researchers will also monitor side effects, quality of life using questionnaires, and survival outcomes for up to two years. Safety evaluations and clinical examinations will be conducted throughout treatment to ensure ongoing participant well-being.

CONDITIONS

Brief Title

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Research Team

P

Patrick Neven, MD, PhD

K

Kristien Borremans, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here